The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Despite being effective, PrEP uptake in Europe remains low due to issues like cost, access, and stigma, hindering its ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

The Trump administration's cuts to HIV prevention will lead to new infections, medical costs and death, experts warn.

A University of Utah biochemist found himself on Time Magazine's 100 most influential people of 2025 list alongside names ...

University of Utah biochemist called ‘Pioneer’ in magazine’s annual list of influencers that includes politicians, ...